Celgene walks away from Oncomed’s navicixizumab
Celgene has decided not to exercise its option to license OncoMed’s bispecific antibody navicixizumab.
Read More
Tag: navicixizumab
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
